学术会议:紧随研究趋势 洞察学术热点 进入>
产业会议:新技术,新领域,深入产业环节 进入>
举办会议及论坛超过百场 邀请海内外院士超过50名 教授PI专家授课超过1000名 总参会人数超过10万人
2019-05-17至2019-05-18 上海
导航

已确认嘉宾Confirmed Guests

Li Zhou VP of CAR-T Cell Therapy

Livzon Mabpharm Inc

Li Zhou VP of CAR-T Cell Therapy

Livzon Mabpharm Inc

Li Zhou, PhD, VP of CAR-T Cell Therapy at Livzon Mabpharm in Zhuhai Guangdong. He helped building the lentivector and CAR-T GMP manufacturing platforms and advanced the first internal CAR-T program into the IND enabling clinical study.  He was previously VP of Cell Engineering at TxCell (now is Sangamo therapeutics) in France. He led the team quickly established a diverse CAR-Treg product pipeline for treating autoimmune disease and organ transplant rejection. His team helped advancing the first-ever CAR-Treg clinical trial for prevention of organ transplant rejection. As CSO and Director of Research at ZMKS international Cancer Therapy Biotechnologies Co., he pioneered the effort in engineering the armed CAR-T cells that can secrete bispecific checkpoint inhibitor antibodies. Prior to this, he was investigator III/lab head in Novartis Biologics Center in Cambridge working on developing bispecific antibody therapeutics, and  CAR-T therapies in collaboration with Dr Carl June at UPenn. He led a number of CAR-T programs including CD22 CAR-T, bispecific CD19/CD22 CAR-T to treat antigen negative relapse in blood cancers, and Mesothelin CAR-T against solid tumors. Top candidates are currently in clinical development at Novartis. He also led the program on developing on-switch regulatable CAR-T.


邀请函

下载邀请函
×
留下姓名电话和邮箱,邀请函直接发送到邮箱
*姓名:
* 电话:
* Email: